Skip to main content

Table 1 Baseline characteristics of the study sample

From: Delayed linkage to HIV care among asylum seekers in Quebec, Canada

 

Overall (n = 139)

First diagnosed in Canada (n = 60)

First diagnosed before arrival to Canada (n = 79)

Age (median [IQR])

38 [33; 45]

37 [33; 44]

39 [33; 47]

Sex

 Female

88 (63%)

31 (52%)

57 (72%)

 Male

51 (37%)

29 (48%)

22 (28%)

Sexual orientation

 Heterosexual

120 (86%)

51 (85%)

69 (87%)

 LGBTQ

19 (14%)

9 (15%)

10 (13%)

Country of origin

 Africa

  Nigeria

33 (24%)

12 (20%)

21 (27%)

  Other

54 (39%)

19 (31%)

36 (46%)

 Latin America

  Haiti

48 (34%)

29 (48%)

19 (24%)

  Other

4 (3%)

0 (0%)

3 (4%)

History of sexual- or gender-based violence

57 (41%)

25 (42%)

32 (41%)

 Rape

35 (25%)

16 (26%)

19 (24%)

CD4 at presentation in Canada, cells/μl (median, range, [IQR])

415,

7–1221,

[275; 656.5]

307,

11–811,

[221; 401]

574,

7–1221,

[382; 756]

 CD4 < 200

22 (16%)

13 (22%)

9 (11%)

 CD4 < 350

52 (37%)

37 (62%)

15 (19%)

Baseline viral load, copies/ml (median, range, [IQR])

1970,

< 20 - > 1 million, [< 20; 41,313]

32,349,

< 20 - > 1 million,

[7890; 100,594]

< 20,

< 20 - > 1 million,

[< 20; 181]

OI at presentation

1 (1%)

1 (2%)

0 (0%)

Requiring primary prophylaxis for OI

23 (16%)

12 (20%)

10 (13%)

cART regimens, baseline

 On cART

61 (44%)

0 (0%)

61 (77%)

  3rd agent

   NNRTI

35 (57%)

0 (0%)

35 (57%)

   PI

5 (8%)

0 (0%)

5 (8%)

   II

16 (26%)

0 (0%)

16 (26%)

   Unknown

4 (7%)

0 (0%)

4 (7%)

  Single tablet regimens

41 (67%)

0 (0%)

41 (67%)

cART regimens, end of study period

 On cART

133 (96%)

58 (97%)

75 (95%)

  3rd agent

   NNRTI

8 (6%)

1 (2%)

7 (9%)

   PI

2 (2%)

0 (0%)

2 (3%)

   II

123 (92%)

57 (98%)

66 (88%)

  Single tablet regimens

103 (77%)

42 (72%)

61 (81%)

TST

 Positive

47 (34%)

16 (27%)

31 (39%)

 Negative

84 (60%)

41 (68%)

43 (54%)

 Not done/missing

8 (6%)

3 (5%)

5 (6%)

Co-infection with HBV

8 (6%)

4 (7%)

4 (5%)

Co-infection with HCV

1 (0.7%)

0 (0%)

1 (1%)

  1. ARV antiretroviral, cART combination antiretroviral therapy, HBV hepatitis B virus, HCV hepatitis C virus, II integrase inhibitor, IQR interquartile range, LGBTQ lesbian, gay, bisexual, transgender, and/or queer, NNRTI non-nucleoside reverse transcriptase inhibitor, OI opportunistic infection, PI protease inhibitor, TST tuberculin skin test